Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer

Chan H. Han, Qingyi Wei, Karen K. Lu, Zhensheng Liu, Gordon Mills, Li E. Wang

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Survivin has been identified as an apoptosis inhibitor and a key regulator of mitosis. A common polymorphism (-31G>C) at the survivin promoter has been extensively studied in various cancers and reported to influence survivin expression. We hypothesize that polymorphisms in the survivin promoter are associated with clinical outcomes of patients with ovarian cancer. In this study, we genotyped all of five common and independent (r2 < 0.25 for all LD) survivin promoter polymorphisms (-1547A/G [rs3764383], -644C/T [rs8073903], -625C/G [rs8073069], -241C/T [rs17878467], and -31G/C [rs9904341]) in 168 patients with primary epithelial ovarian cancer, using the polymerase chain reaction-restriction fragment length polymorphism method. We found that -1547A/G and -31G/C were significantly associated with age of disease onset. Compared with patients with the -1547GG genotype, the -1547AA genotype showed a significantly younger age of disease onset (58.8 years vs. 70.1 years; P = 0.001); the -31CC genotype had a decrease, though not significant, in the age of disease onset, compared with patients with the -31GG genotype (57.1 years vs. 62.8 years; P = 0.058). The numbers of -1547A and -31C alleles were associated with a decrease in age of onset in an allele-dose response manner (P trend = 0.001 and 0.026, respectively). However, no association was found between survivin polymorphisms and patients' prognosis, except for -625C/G SNP in 37 patients with a persistent disease. The findings suggest that the promoter variants of survivin may have an effect on age of onset of ovarian cancer. Validation studies with larger sample sizes are warranted.

Original languageEnglish (US)
Pages (from-to)289-299
Number of pages11
JournalInternational Journal of Clinical and Experimental Medicine
Volume2
Issue number4
StatePublished - Dec 1 2009
Externally publishedYes

Fingerprint

Polymorphism
Age of Onset
Ovarian Neoplasms
Genotype
Alleles
Polymerase chain reaction
Validation Studies
Mitosis
Restriction Fragment Length Polymorphisms
Sample Size
Single Nucleotide Polymorphism
Apoptosis
Polymerase Chain Reaction
C 31G
Neoplasms

Keywords

  • Apoptosis
  • BIRC5
  • Genetic polymorphism
  • Ovarian cancer
  • Survival

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. / Han, Chan H.; Wei, Qingyi; Lu, Karen K.; Liu, Zhensheng; Mills, Gordon; Wang, Li E.

In: International Journal of Clinical and Experimental Medicine, Vol. 2, No. 4, 01.12.2009, p. 289-299.

Research output: Contribution to journalArticle

Han, Chan H. ; Wei, Qingyi ; Lu, Karen K. ; Liu, Zhensheng ; Mills, Gordon ; Wang, Li E. / Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. In: International Journal of Clinical and Experimental Medicine. 2009 ; Vol. 2, No. 4. pp. 289-299.
@article{faab2230a2104a61b8b7e6148a88f04b,
title = "Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer",
abstract = "Survivin has been identified as an apoptosis inhibitor and a key regulator of mitosis. A common polymorphism (-31G>C) at the survivin promoter has been extensively studied in various cancers and reported to influence survivin expression. We hypothesize that polymorphisms in the survivin promoter are associated with clinical outcomes of patients with ovarian cancer. In this study, we genotyped all of five common and independent (r2 < 0.25 for all LD) survivin promoter polymorphisms (-1547A/G [rs3764383], -644C/T [rs8073903], -625C/G [rs8073069], -241C/T [rs17878467], and -31G/C [rs9904341]) in 168 patients with primary epithelial ovarian cancer, using the polymerase chain reaction-restriction fragment length polymorphism method. We found that -1547A/G and -31G/C were significantly associated with age of disease onset. Compared with patients with the -1547GG genotype, the -1547AA genotype showed a significantly younger age of disease onset (58.8 years vs. 70.1 years; P = 0.001); the -31CC genotype had a decrease, though not significant, in the age of disease onset, compared with patients with the -31GG genotype (57.1 years vs. 62.8 years; P = 0.058). The numbers of -1547A and -31C alleles were associated with a decrease in age of onset in an allele-dose response manner (P trend = 0.001 and 0.026, respectively). However, no association was found between survivin polymorphisms and patients' prognosis, except for -625C/G SNP in 37 patients with a persistent disease. The findings suggest that the promoter variants of survivin may have an effect on age of onset of ovarian cancer. Validation studies with larger sample sizes are warranted.",
keywords = "Apoptosis, BIRC5, Genetic polymorphism, Ovarian cancer, Survival",
author = "Han, {Chan H.} and Qingyi Wei and Lu, {Karen K.} and Zhensheng Liu and Gordon Mills and Wang, {Li E.}",
year = "2009",
month = "12",
day = "1",
language = "English (US)",
volume = "2",
pages = "289--299",
journal = "International Journal of Clinical and Experimental Medicine",
issn = "1940-5901",
publisher = "e-Century Publishing Corporation",
number = "4",

}

TY - JOUR

T1 - Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer

AU - Han, Chan H.

AU - Wei, Qingyi

AU - Lu, Karen K.

AU - Liu, Zhensheng

AU - Mills, Gordon

AU - Wang, Li E.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Survivin has been identified as an apoptosis inhibitor and a key regulator of mitosis. A common polymorphism (-31G>C) at the survivin promoter has been extensively studied in various cancers and reported to influence survivin expression. We hypothesize that polymorphisms in the survivin promoter are associated with clinical outcomes of patients with ovarian cancer. In this study, we genotyped all of five common and independent (r2 < 0.25 for all LD) survivin promoter polymorphisms (-1547A/G [rs3764383], -644C/T [rs8073903], -625C/G [rs8073069], -241C/T [rs17878467], and -31G/C [rs9904341]) in 168 patients with primary epithelial ovarian cancer, using the polymerase chain reaction-restriction fragment length polymorphism method. We found that -1547A/G and -31G/C were significantly associated with age of disease onset. Compared with patients with the -1547GG genotype, the -1547AA genotype showed a significantly younger age of disease onset (58.8 years vs. 70.1 years; P = 0.001); the -31CC genotype had a decrease, though not significant, in the age of disease onset, compared with patients with the -31GG genotype (57.1 years vs. 62.8 years; P = 0.058). The numbers of -1547A and -31C alleles were associated with a decrease in age of onset in an allele-dose response manner (P trend = 0.001 and 0.026, respectively). However, no association was found between survivin polymorphisms and patients' prognosis, except for -625C/G SNP in 37 patients with a persistent disease. The findings suggest that the promoter variants of survivin may have an effect on age of onset of ovarian cancer. Validation studies with larger sample sizes are warranted.

AB - Survivin has been identified as an apoptosis inhibitor and a key regulator of mitosis. A common polymorphism (-31G>C) at the survivin promoter has been extensively studied in various cancers and reported to influence survivin expression. We hypothesize that polymorphisms in the survivin promoter are associated with clinical outcomes of patients with ovarian cancer. In this study, we genotyped all of five common and independent (r2 < 0.25 for all LD) survivin promoter polymorphisms (-1547A/G [rs3764383], -644C/T [rs8073903], -625C/G [rs8073069], -241C/T [rs17878467], and -31G/C [rs9904341]) in 168 patients with primary epithelial ovarian cancer, using the polymerase chain reaction-restriction fragment length polymorphism method. We found that -1547A/G and -31G/C were significantly associated with age of disease onset. Compared with patients with the -1547GG genotype, the -1547AA genotype showed a significantly younger age of disease onset (58.8 years vs. 70.1 years; P = 0.001); the -31CC genotype had a decrease, though not significant, in the age of disease onset, compared with patients with the -31GG genotype (57.1 years vs. 62.8 years; P = 0.058). The numbers of -1547A and -31C alleles were associated with a decrease in age of onset in an allele-dose response manner (P trend = 0.001 and 0.026, respectively). However, no association was found between survivin polymorphisms and patients' prognosis, except for -625C/G SNP in 37 patients with a persistent disease. The findings suggest that the promoter variants of survivin may have an effect on age of onset of ovarian cancer. Validation studies with larger sample sizes are warranted.

KW - Apoptosis

KW - BIRC5

KW - Genetic polymorphism

KW - Ovarian cancer

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=74549178973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549178973&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 289

EP - 299

JO - International Journal of Clinical and Experimental Medicine

JF - International Journal of Clinical and Experimental Medicine

SN - 1940-5901

IS - 4

ER -